Opinion|Videos|August 5, 2024
Targeting of HER3: Insights from HERTHENA-Lung01
Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.
Advertisement
Episodes in this series
- Please discuss the role of HER3 in the development of resistance to EGFR targeted therapies. (
Manickavasagar, et al. Lung Cancer Mang, 2021 ;Engelman, et al. Science, 2007 )- Describe the rationale for targeting HER3 in patients with EGFR TKI resistance.
- What have data shown with treatment strategies using dual targeting of HER3 and EGFR?
- Please review the rationale and study design for HERTHENA-Lung01 and discuss emerging study data and its implications on the treatment landscape. (
Goto, et al. WCLC 2023. Abstract OA05.03 ;Johnson, et al. ESMO 2023. Abstract 1319MO )- Briefly outline the study design and key endpoints. What are your perceptions around the brain mets data presented at ESMO this past year?
- What are some key takeaways from safety data?
- What implications may these findings have on clinical practice?
Advertisement
Related to this article
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
5